Navigation Links
Identifying subsets of patients who will respond to subsequent lines of chemotherapy
Date:10/9/2010

In a study presented at the 35th Congress of the European Society for Medical Oncology (ESMO), Dr Giovanni Bernardo from Fondazione Maugeri in Pavia, Italy, presented results that suggested it may be possible to identify subsets of metastatic breast cancer patients who are likely to respond to subsequent lines of chemotherapy.

Dr Bernardo's group analysed data from 980 women treated with chemotherapy for metastatic breast cancer in their centre between 1992 and 2006.

They found that the median overall survival grew progressively smaller for each successive chemotherapy regimen the patients were given. The time to treatment failure also shortened as each new regimen was tried, from a median of 9.2 months for first-line therapy, to 7.8 and 6.4 months for the second and third-line drugs. Beyond the third line, there was no significant decrease in the medial time to treatment failure for each successive therapy.

The researchers found that only one factor they analysed affected a patient's overall survival time. That factor was the time to treatment failure for each line of chemotherapy. In other words, the more benefit one type of therapy offered, the more benefit the subsequent therapy was likely to offer.

"The implications of our analysis for clinical practice concern the possibility of deciding which patients should be offered a third- or successive chemotherapy line, considering that there are multiple treatment options available today for metastatic disease, and increasing numbers of patients ask for more options when a particular treatment fails," said Dr Bernardo.


'/>"/>

Contact: Vanessa Pavinato
media@esmo.org
European Society for Medical Oncology
Source:Eurekalert

Page: 1

Related biology news :

1. Biomarkers for identifying infant infections
2. Identifying mega-targets for high-yield plant breeding
3. Musicians have biological advantage in identifying emotion in sound
4. Women outperform men when identifying emotions
5. A sticky solution for identifying effective probiotics
6. University of the Basque Country develops system for identifying illnesses in Paraguay
7. Identifying molecular targets for diabetes-related ED
8. Cellulosic ethanol: Expanding options, identifying obstacles
9. Identifying federal research dollars for ag
10. Scripps scientists develop test providing new pathway for identifying obesity, diabetes drugs
11. For insulin sensitive overweight patients, 1 session of exercise improves metabolic health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... of Standards and Technology (NIST) need a special ... often prove that necessity is truly the mother ... M. Lorna De Leoz and Stephen Stein, NIST ... Glycomics is the study of the abundant, often-branched ... proteins and lipids and influence cellular processes, including ...
(Date:7/11/2014)... 3, 2014, Shenzhen, China Researchers from Salk Institute ... the first time evaluated the safety and reliability ... successfully developed a new method, TALEN-HDAdV, which could ... stem cell (hiPSC). This study published online in ... theoretical foundation for stem cell-based gene therapy. , ...
(Date:7/11/2014)... the Max Planck Institute for Medical Research in Heidelberg, ... photosynthesis, the process by which the Earth first gained ... which is therefore crucial for all higher forms of ... first direct visualization of a crucial event in the ... protein complex, photosystem II, splits water into hydrogen and ...
Breaking Biology News(10 mins):A new genome editing method brings the possibility of gene therapies closer to reality 2A first direct glimpse of photosynthesis in action 2
... available in Spanish . Learning more ... used by U.S. Department of Agriculture (USDA) scientists to identify ... bed bugs over the last decade has caused problems in ... and even places of work. The small, blood-feeding insects are ...
... have found that one of the most aggressive invasive ant ... appears to have met its match in the Asian needle ... ant is successfully displacing Argentine ants in an urban environment, ... sting may be the next invasive species to see ...
... MDIf you have an overactive bladder or incontinence, help could be ... FASEB Journal , shows that the epithelium, a ... is able to sense how full the bladder is through the ... bladder becomes full, the cells in the epithelium stretch and become ...
Cached Biology News:Studying bed bug actions for new management tactics 2Researchers find Asian needle ants displacing other aggressive invaders 2Got to go? Harvard scientists figure out how you know 2
(Date:7/11/2014)... 2014 , Not for release, publication ... from any jurisdiction where to do so would constitute a ... Shire plc ("Shire" or the "Company") (LSE: SHP, NASDAQ: ... confirms it has held a meeting with representatives of AbbVie. ... the prior agreement or approval of AbbVie. A ...
(Date:7/11/2014)... 2014 /CNW/ - Sunovion Pharmaceuticals Canada Inc. (Sunovion) today ... acetate) for use as a once-daily adjunctive therapy for ... who are not satisfactorily controlled with conventional therapy.  APTIOM ... under 18 years of age. Epilepsy ... according to Epilepsy Canada, it affects 0.6% of the ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Product ... in very low abundance and are often “lost ... and time-consuming. , Join presenters Dr. Rowel Tobias, ... Dr. John Anders, Head of Quality at Nanotherapeutics, ... approach that can speed detection and quantitation while ...
(Date:7/10/2014)... CA (PRWEB) July 10, 2014 Unraveling ... closer together. The Archer Family purchased a ... within DNA, but ended up with a lifetime of ... contained within the family members’ DNA genuinely brought the ... decided to search deeper into genetic history and prior ...
Breaking Biology Technology:Shire plc - Statement re: Media Speculation 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5
... N.J., July 10 Senesco Technologies , Inc. ... announced that, on July 9, 2009, the Company entered into a ... sale of (i) up to 1,111,111 shares of its common stock ... to purchase an aggregate of up to 1,000,000 shares of common ...
... of Energy,s Lawrence Berkeley National Laboratory and the University ... fabricate efficient solar cells from low-cost and flexible materials. ... of nanoscale pillars, each a single crystal, with dimensions ... take advantage of abundant solar energy we have to ...
... July 9 PharmAthene, Inc. (NYSE Amex: ... biological and chemical threats, today announced that the U.S. ... of the Company,s proposed development plan for SparVax(TM), PharmAthene,s ... , In response to amendments to the request ...
Cached Biology Technology:Senesco Technologies Enters Into Agreement For Up To $1.0 Million In Financing 2Senesco Technologies Enters Into Agreement For Up To $1.0 Million In Financing 3Senesco Technologies Enters Into Agreement For Up To $1.0 Million In Financing 4Nanopillars promise cheap, efficient, flexible solar cells 2Nanopillars promise cheap, efficient, flexible solar cells 3PharmAthene's 2nd Generation rPA Anthrax Vaccine, SparVax(TM), Completes FDA Regulatory Strategy Review 2PharmAthene's 2nd Generation rPA Anthrax Vaccine, SparVax(TM), Completes FDA Regulatory Strategy Review 3PharmAthene's 2nd Generation rPA Anthrax Vaccine, SparVax(TM), Completes FDA Regulatory Strategy Review 4
... and PowerPac 3000 system, 220-240 V, is used ... 50 cm vertical slab gel format. The system ... is capable of separating nucleic acids with single ... (IPC) assembly (IPC and bonded inner glass plate, ...
... Plus overlay agarose is used for ... IPG strips in place in PROTEAN ... is incorporated to allow monitoring of ... of 0.75% agarose in 1x Tris, ...
... The PowerPac HV high-voltage power supply, with ... increased output of 5,000 V, 500 mA, and ... monitor gel temperature between 0 and 90 degrees ... wireless data transfer. Power cord and instructions are ...
The stirbar is used in the buffer tank of the Trans-Blot Plus cell to maintain uniform conductivity and temperature during electrophoretic transfer. Dimensions are 3.5 x 0.5 in....
Biology Products: